Interferon-␥ is a cytokine which is believed to play a role in both the
Introduction
Interferon-␥ (␥IFN) is a cytokine which has been implicated in the protection against intracellular organisms and the development of autoimmune disease. Specifically, increased ␥IFN production has been described in both humans with systemic lupus erythematosus (SLE) and murine models of SLE. Humans with SLE have been described both with increased serum levels [1] [2] [3] [4] [5] and with increased production from peripheral blood mononuclear cells (PBMC) in culture. 6, 7 There has not been a correlation of ␥IFN production or levels and disease activity. A recent description of a CA minisatellite repeat in the first intron of the ␥IFN gene suggested that there might be a variation in production related to, or linked to this polymorphism. 8 Indeed, one study demonstrated that individuals homozygous for allele 2 produced higher levels of ␥IFN after concanavalin A stimulation of peripheral blood mononuclear cells compared to the other alleles. 9 The interferon gene maps to chromosome 12q24.1 which is a region that has demonstrated some modest linkage in Caucasian SLE families in one of the three large genome-wide screens for SLE. 10 This suggested that this region might be important in the development or predis- position to SLE. Supportive evidence comes from a study which demonstrated that an amino acid polymorphism in the receptor for ␥IFN is strongly associated with SLE and leads to decreased HLA DR expression on B cells and increased numbers of IL-4 expressing T cells.
11
Murine models support the idea that overexpression of ␥IFN contributes both to the susceptibility and to the pathogenesis of SLE. An important model in which transgenic ␥IFN is expressed at high levels in the skin of mice, spontaneously develops the classical serologic findings of human lupus and has renal immunoglobulin deposits. 12 One of the most widely used murine lupus models, the MRL/lpr mouse, has large numbers of CD3
− T cells in blood and lymphoid structures. These cells over-produce tumor necrosis factor-␣ and ␥IFN. 13 When these mice are bred onto the ␥IFN receptor knockout mice, there is a decrease in anti-dsDNA antibodies and a reduction in nephritis. 14, 15 When the ␥IFN ligand knockout was bred onto the MRL/lpr strain, these mice also had a reduction in nephritis although the auto-antibodies were unchanged. 16, 17 Similar findings were seen when another murine model, the (NZB × NZW)F1, was bred with the receptor or ligand knockout mice. 18 These data suggested that genetic differences in ␥IFN production might contribute to the susceptibility to SLE. We examined the frequency of eight CA repeat alleles in the first intron of the ␥IFN gene in SLE patients and controls.
Results
Eight alleles were identified through sequencing and PCR analysis. The most common allele previously reported and that which is found in GenBank, is allele 2 which contains 12 CA repeat units. Allele 1 contains 11 CA repeats, allele 3 contains 13 CA repeats, etc. Allele 8 was found only in two Asian controls. In addition, a single nucleotide polymorphism was found at position 1348 (M7265). This nucleotide is a thymidine in the GenBank entry but thymidine was an infrequent polymorphism in our sequence analysis with adenine having a gene frequency of 0.735. In a limited study, there was no difference in frequency between patients and controls. All carriers of the T variant also carried the 2 allele, however, haplotype studies were not performed to determine linkage. Although the wild-type sequence converts a CT to a CA, we use the previous nomenclature 9 for the alleles and do not count that as a repeat segment. The allele frequencies in the control and SLE populations are given in Table 1 . The controls and patients were recruited consecutively from Baltimore and Philadelphia during the study and included multiple ethnicities. Only Caucasoid and African American patients and controls are separately evaluated. In our study populations, allele 3 was found more frequently than allele 2. We also identified three additional alleles that had not been previously described (alleles 6, 7, and 8). There were no significant differences between the allele frequencies in the control and SLE populations (the P values are not shown). Neither was there a significant difference between African American and Caucasoid controls.
To determine whether any specific allele was associated with a particular phenotype, the frequency of a specific allele seen with each phenotype was compared to those without the phenotypic feature. The patient information includes at least 2 years of observation and clinical features given in the table are cumulative. There is no difference in follow-up or observation for either ethnicity. Those results are shown in Table 2 with P values less than 0.05 underlined. Allele 2 was under-represented in patients with arthritis and anti-La antibodies. Nephrotic syndrome was associated with a decreased representation of allele 3 and increased representation of alleles 2 and 6. Allele 6 was associated with more serious manifestations of lupus (renal disease, fever, anti-RNP, and cytotoxic drug use). There were a small number of patients with gastrointestinal manifestations of lupus including ulcers, pancreatitis, and motility disorders. These patients largely carried allele 1, however, they are not reported in the table due to their infrequent occurrence. Separate analyses were not performed for African American and Caucasoid patients because the distribution of alleles is identical. We therefore cannot completely rule out racespecific allele effects.
A previous study had identified allele 2 as being asso- Genes and Immunity ciated with increased production of ␥IFN in stimulated cultures of peripheral blood mononuclear cells. 9 We had hypothesized that increased ␥IFN production would be associated with SLE or with more severe manifestations of SLE. To confirm that there were differences in ␥IFN production related to the alleles, peripheral blood mononuclear cells were stimulated with concanavalin A. Seven donors homozygous for allele 2, seven donors homozygous for allele 3, eight donors heterozygous for allele 2/3, and nine donors heterozygous for either 2 or 3 were tested. ␥IFN was measured in both unstimulated and stimulated cell supernatants. Unstimulated cultures gave very low levels of ␥IFN and there were no differences attributable to the different alleles. Stimulated cultures confirmed that donors homozygous for allele 2 produced the highest levels of ␥IFN, although the difference did not reach statistical significance (Table 3 and Figure 1 ). People heterozygous for alleles 2/3 were midway between those carrying alleles 2/2 or 3/3. This study provides provocative preliminary evidence that genetic variation at the ␥IFN locus may modify ␥IFN production.
Discussion
There are three compelling reasons to believe that genetic variation resulting in increased ␥IFN production might affect the susceptibility or pathogenesis of SLE. (1) Patients with SLE produce high levels of ␥IFN both in vivo and in vitro. [1] [2] [3] [4] [5] [6] [7] (2) One genome-wide screen found a slight association of SLE with chromosome 12q24.1 in Caucasoids. 10 (3) Murine models demonstrate that overexpression of ␥IFN is deleterious in terms of the development of lupus and either genetic or medical blockade of ␥IFN ameliorates disease. 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] This study demonstrated that none of the seven alleles were associated with SLE. Instead, an effect was seen in the manifestations of the disease. Allele 2 was protective for arthritis. Allele 4 was associated with both malar rash and topical corticosteroid use, while allele 6 was associated with markers of more severe disease activity.
The in vitro data suggests that these CA repeats may be associated directly or indirectly (through linkage) with distinct patterns of ␥IFN production. Our analyses of phenotypic features associated with each of the alleles demonstrated distinct phenotypic features associated with particular alleles. The consistency of the findings suggests that the associations with allele 6 represent biologically relevant associations. Allele 6 was associated with use of cytotoxic drugs, nephrotic syndrome, renal insufficiency, thrombocytopenia, anti-RNP, and fever. a n = number of patients with the given feature. The numbers under each allele type represent the number of patients bearing that allele (ie, homozygous patients are listed once, heterozygous twice). Reported as the Mann-Whitney two-tailed P value. c x refers to any allele other than 2 or 3.
These are all markers of severe disease. Interestingly, allele 3, which is associated with decreased ␥IFN production was found less frequently in patients with nephrotic syndrome. Taken together, these data support a role for genetic variation in the ␥IFN gene as a modifier of the course of SLE. 
Materials and methods

Study population
Ninety-nine controls and 136 SLE patients were used. The control and the SLE patient samples were collected from Eastern seaboard populations (Baltimore and Philadelphia). Controls were excluded if they had autoimmune disease or a first-degree relative had SLE. Ethnicity is self reported for both patients and controls. The SLE patients are part of the Johns Hopkins Lupus Cohort. Patient inclusion in this cohort is based on a clinical diagnosis of SLE. The cumulative database on each patient is updated yearly with clinical and laboratory data being obtained every 3 months. The data presented in Table 2 is, therefore, cumulative and represents a minimum of 2 years observation. Clinical information on this population has been previously reported. 23, 24 Informed consent and IRB approval for these studies were obtained.
PCR analysis
The first intron dinucleotide repeat was amplified using: 5Ј-gct gtc ata ata ata ttc aga c-3Ј (forward primer) and 5Ј-gga act atc ttt taa agc tcg-3Ј (reverse primer). 9 Samples were amplified using dATP [ 35 S]. Amplification results in a product which is 80 base pairs in length in the wildtype allele given in GenBank. PCR products were denatured in 95% formamide at 95°C and run on a denaturing 6% sequencing gel (Sequenase). At least one sample of each allele was fully sequenced. Samples of known alleles were run on each gel for comparison.
Cell stimulation
Two × 10 5 peripheral blood mononuclear cells were cultured with or without 5 g/ml concanavalin A in 0.2 ml of media for 18 h. Supernatants from triplicate cultures from each healthy control donor were harvested and analyzed by ELISA (PBL Biomedical Laboratories, New Brunswick, NJ, USA).
Statistical analysis
ELISA results were compared using the Mann-Whitney test. Comparisons between allele frequencies in controls and patients were performed using the 2 statistical test. Comparisons of allele frequencies in different patient subgroups utilized Fisher's exact test. A correction for multiple comparisons was not performed.
